The global neuroendocrine carcinoma market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increase in the number of cases of neuroendocrine tumors across the globe and rapid development in the tumor therapy.
Neuroendocrine carcinoma is a condition in which cancer develops in the neuroendocrine cells that secretes hormones into the body. This type of cancer causes tiredness and weight loss of patients. In this condition, the tumor grows painfully in neuroendocrine system of the body and have similar neuroendocrine cells.
Request Free Sample Report Here
These similar cells are observed in organs such as kidneys, intestines, stomach, lungs that help control the speed of food through gastrointestinal tract and blood flow through the lungs. This tumor is a rare pernicious disorder that accounts for nearly one percent of all pernicious disorders. Some symptoms associated with neuroendocrine carcinoma are hypoglycemia, loss of appetite, headache, gastric ulcer, jaundice, diarrhea, unusual bleeding, fever persistent in specific area, and anxiety.
Around 12,000 people in the U.S. are diagnosed with neuroendocrine carcinoma each year, enlisted in the report by the American Society of Clinical Oncology. According to a report published by U.S. Surveillance Epidemiology and End Results Register, neuroendocrine carcinoma has expanded around 500%, compared prior to 2016. This is expected to provide growth opportunities for the market in the coming years.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing investment in research and development programs for the development of inexpensive next-generation sequencing tools and the ongoing clinical practices are expected to boost the market growth.
- Rising demand for curative method for pancreatic NETs and wide adoption of radiofrequency ablation are expected to drive the market growth.
- Governments’ policies for awareness initiatives and encouragement for the development of advanced treatment devices for neuroendocrine carcinoma is a key factor that can push the market growth.
- Major issues regarding severe consequences in the process of diagnosis such as bleeding, tumor spread, and pancreatic fistula are expected to hinder the adoption of the treatment. This is a key restraining factor of the market expansion.
- High cost of the diagnosis and prolonged treatment are some key factors expected to hamper the market growth during the forecast period.
Market Segment Insights
Gastrointestinal segment is expected to grow at a rapid pace
Based on sites, the global neuroendocrine carcinoma market is divided into lung, brain, pancreas, gastrointestinal, and others. The gastrointestinal segment is expected to grow at a rapid pace in the coming years as the majority of the cancer type is largely associated with gastric problems and several technology are available for the treatment. However, the lung segment is projected to hold a key market share during the forecast period owing to lungs affection due to tumor formation and rising cases of lungs tumor worldwide.
North America is anticipated to constitute a key market share
In terms of regions, the global neuroendocrine carcinoma market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share in the coming years owing to new technology developments for the diagnosis neuroendocrine carcinoma and wide R&D investment from key players based in the region. Moreover, the presence of major global players in the region especially in the US present another key driver for the regional market growth. On the other hand, the market of Asia Pacific is anticipated to expand at a rapid pace during the forecast period due to the increase in the number of cases of NETs in the region. Furthermore, the wide prevalence of tumor cases among a large number of the people and increasing investment in the healthcare industry in the region play critical roles in the market expansion of Asia Pacific.
Compititive Landscape
Key players competing in the global neuroendocrine carcinoma market are Novartis AG; Amgen Inc.; Boehringer Sohn AG & Ko. KG; Dauntless Pharmaceuticals, Inc.; Hutchison MediPharma Ltd.; AVEO Pharmaceuticals Pvt. Ltd.; Chiasma Inc.; Aegis Therapeutics LLC; Progenics Pharmaceuticals, Inc.; Tarveda Therapeutics, Inc.; Pfizer Inc.; Jubilant Life Sciences Ltd.; AbbVie Inc.; Delcath Systems, Inc.; and Exelixis, Inc.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
A recent market study published by Future Market Insights (FMI) on the neuroendocrine carcinoma treatment market includes global industry analysis for 2014-2018 and opportunity assessment for 2019-2029 and delivers a comprehensive assessment of the most important market dynamics.
After conducting thorough research on the historical as well as current growth parameters of the neuroendocrine carcinoma treatment market, the growth prospects of the market are obtained with maximum precision.The global neuroendocrine carcinoma treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.Disease IndicationGastric Neuroendocrine TumorsLung Neuroendocrine TumorsPancreatic Neuroendocrine TumorsAppendiceal Neuroendocrine TumorsFor more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1278 Treatment TypeSomatostatin AnalogsTargeted TherapyChemotherapyEnd UserHospitalsClinicsOncology CentersAmbulatory Surgical CentersFor Information On The Research Approach Used In The Report, Request Methodology@ https://www.futuremarketinsights.com/askus/rep-gb-1278RegionNorth AmericaLatin AmericaWestern EuropeEastern EuropeAPEJJapanMEAThe research report on global neuroendocrine carcinoma market covers analysis on key companies dealing with neuroendocrine carcinoma.
Various aspects such as SWOT analysis, key developments, innovations, product portfolio, financials and company overview are included in this section of the report.
The reader can gain intelligence on the major players that have a good hold in the market, based on which new strategies can be devised to gain an edge on the competition.
The weighted market analysis on global neuroendocrine carcinoma market delivers value to the reader by providing drinkable insights, ready to use statistical analysis and recommendations without biasness in order to plan future expansion strategies and also to gain stability in the changing dynamics of the global market.
The worldwide neuroendocrine tumor treatment market size was assessed at USD 1.51 billion in 2017 and is required to enlist a CAGR of 10.4% during the estimated time frame.
Expanding instances of neuroendocrine tumors (Neuroendocrine Tumor Treatments) are required to speed up the interest for treatment alternatives, accordingly increasing the market development over the gauge time frame.
Progressing R exercises in discovery procedures, for example, Ga named radionucleotide treatments and radiofrequency removal strategy, are the central point driving the interest in Neuroendocrine Tumor Treatment market.
For example, PSMA Targeted PET Imaging Agent by Progenics Pharmaceuticals, Inc. is under the clinical preliminary stage and is required to assist with treating prostate malignant growth.
Hefty interests in the field by malignancy research associations and governments across the globe is another key factor pushing the Neuroendocrine Tumor Treatment market development.
For example, associations, like The Neuroendocrine Tumor Research Foundation (Neuroendocrine Tumor Treatment RF), put more than USD 1.5 million in the improvement of cutting edge radiation treatment named Peptide Receptor Radionuclide Therapy (PRRT).
